Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 P213 | DOI: 10.1530/endoabs.99.P213

ECE2024 Poster Presentations Endocrine-Related Cancer (40 abstracts)

Endocrine autoimmunity during immunotherapy for cancer – a snapshot from an Oncologic Institute in Romania

Elena Lazar 1 , Ioana Andreescu 2 , Ana Lazar 3 , Simona Coniac 3 & Corin Badiu 2,3


1Institute of Oncology, Bucharest, Endocrinology, Bucharest; 2National Institute of Endocrinology, Endocrinology IV, Bucuresti; 3Carol Davila University of Medicine and Pharmacy, Bucharest


Background: In the last decade, immunotherapy proved to be the frontline in the fight against cancer in a rocketing area of cancer types. Boosting the body’s inherent immune system, a new set of toxicities raised, labeled as immune-related adverse events (irAEs). Endocrine disorders, particularly thyroid dysfunctions, are by far the most frequent irAEs during immune checkpoint inhibitors (ICIs) therapy. New research data explored their predictive impact in cancer patients’ overall survival. An in-depth endocrinological specific study was performed to evaluate endocrine irAEs caused by ICIs.

Methods: This is a retrospective analysis of endocrine irAEs from a cohort of cancer patients (mainly lung cancer and malignant melanoma) treated with ICIs in the Oncology Institute ‘Prof. Dr. Alexandru Trestioreanu’, Bucharest, Romania, from 1 October 2022 to 31 December 2023. The Institute endocrinologist assessed, followed and subsequently treated all the occurring endocrinopathies during immunotherapy. Endocrine irAEs were evaluated according to current medical practice based on routine clinical, biological and imaging criteria.

Results: Of 22 cancer patients that developed endocrine irAEs, we identified 5 cases of hypophysitis, 18 cases of thyroid disorder, 1 case of primary adrenal insufficiency, with one or more endocrine glands being affected. The anterior pituitary disorder involving several hormonal axes such as, thyroid, adrenal and gonadotropic deficiencies were common, with no proof of growth hormone deficit or hypoprolactinemia.

Conclusions: The expected increasing number of both malignancies and ICIs-treated cancer patients in the future exposes the endocrinologist face to face to a new area of pathology. Diagnosing and managing endocrine irAEs requires a collaborative effort between the oncologist and the endocrinologist to promote a better quality of life and a higher survival rate for cancer patients.

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.